Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Status:
Recruiting
Trial end date:
2029-11-19
Target enrollment:
Participant gender:
Summary
The aim of this study is to support development of asciminib in the pediatric population (1
to <18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of
asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on
the concept that CML in the pediatric population has the same pathogenesis, similar clinical
characteristics and progression pattern as in adults.